Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00469079 · ClinicalTrials.gov registry record · Phase 2
Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00469079 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 130 participants.
The verdict
NCT00469079, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
The use of smokeless tobacco (ST) as a substitute for cigarette smoking has been suggested since it is considered by some to be a less harmful tobacco product (Russell, Jarvis and Feyerabend, 1980; Russell et al, 1981; Rodu, 1994). ST does not have the volatile constituents and carbon monoxide (CO) that are found in cigarette smoke. Since ST is not smoked there would be less risk of cardiovascular and lung disease. In addition the harm associated with second hand smoke would be eliminated. Although the health risks are reduced in ST users, they still exist due to the presence of nitrosamines found in ST. A better approach would be to use nicotine replacement that did not contain carcinogens, however the cost of such NRT could be prohibitive especially in third world countries where the rate of smoking is continuing to rise and the per capita income is much lower than in the United States. Purpose: The goal of this study is to evaluate the health effects of Camel Snus, the new oral tobacco product produced by RJ Reynolds and Taboka, produced by Phillip Morris. These products are pasteurized rather than fermented and contain less moisture to eliminate spitting. They are marketed as an alternative to cigarette smoking.
Interventions
- OTHER Camel Snus
- DRUG Nicotine gum and lozenge
- OTHER Taboka
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00469079
The ClinicalTrials.gov registry entry for NCT00469079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Camel Snus is the first listed.
NCT00469079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00469079 about?
NCT00469079 is a clinical study titled "Health Effects of SLT, Cigarette Smoking, and New Tobacco Products". The use of smokeless tobacco (ST) as a substitute for cigarette smoking has been suggested since it is considered by some to be a less harmful tobacco product (Russell, Jarvis and Feyerabend, 1980; Russell et al, 1981; Rodu, 1994). ST does not have the volatile constituents and carbon monoxide (CO) ...
What is the current status of trial NCT00469079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2007-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00469079?
The interventions under investigation include: Camel Snus (OTHER), Nicotine gum and lozenge (DRUG), Taboka (OTHER).
Who is sponsoring clinical trial NCT00469079?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.